Accustem Sciences Inc.
ACUT evidence brief
What we can confirm
- BioSniper Score:
- 4.2 / 10
- Market Cap:
- $2.4M
- Lead Asset:
- MSC (Phase 2)
What it means
What to watch
Prepared research question
What matters most for ACUT—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · ACUT
Accustem Sciences Inc. (ACUT) is a development-stage diagnostics company advancing two laboratory-developed tests (LDTs) — a 20-gene prognostic assay for early-stage breast cancer and a microRNA signature classifier for ischemic stroke — both processed through its partner EmeritusDx, with minimal revenue and negative shareholders' equity as of mid-2026.
Key risk: Negative equity
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Market Cap
$2.4M
Cash Runway
—
Lead Asset
MSC (Phase 2)
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 2 pipeline candidates for Accustem Sciences Inc..
Similar companies
Accustem Sciences Inc. (ACUT) is a development-stage diagnostics company advancing two laboratory-developed tests (LDTs) — a 20-gene prognostic assay for early-stage breast cancer and a microRNA signature classifier for ischemic stroke — both processed through its partner EmeritusDx, with minimal revenue and negative shareholders' equity as of mid-2026.
- Total revenue was $0.1M and net income was -$0.3M for the period ended 2026-06-30 [sec].
- Shareholders' equity was -$4.1M as of 2026-06-30 [sec].
- Lead pipeline candidate StemPrintER is a 20-gene prognostic assay for early-stage breast cancer (luminal ER+/HER2-), currently in preclinical phase and classified as an LDT [pipeline].
- Second pipeline candidate MSC is a 24-microRNA signature classifier for ischemic stroke, currently in Phase 2 and also classified as an LDT [pipeline].
- Both assays are processed, tested, and reported by partner EmeritusDx [pipeline].
What works
- StemPrintER targets a well-defined niche — early-stage luminal ER+/HER2- breast cancer — with a clear competitive landscape including established assays such as OncotypeDX and MammaPrint [pipeline].
- The MSC assay for ischemic stroke addresses a large unmet need, with no direct competitor listed in the same indication [pipeline].
- Partnering with EmeritusDx for laboratory processing may reduce capital expenditure and operational complexity [pipeline].
What to weigh
- The company had negative shareholders' equity of -$4.1M as of 2026-06-30, indicating liabilities exceed assets [sec].
- Revenue was only $0.1M with a net loss of -$0.3M for the period ended 2026-06-30, reflecting minimal commercial traction [sec].
- Both pipeline candidates are LDTs, which face regulatory uncertainty and reimbursement challenges compared to FDA-approved tests [pipeline].
- StemPrintER is still in preclinical phase, far from generating revenue, while the MSC assay is in Phase 2 with no disclosed timeline for completion [pipeline].
From the filings
Quoted directly from source documents.
StemPrintER is a 20-gene prognostic assay for early-stage breast cancer
“Pipeline Candidate: StemPrintER Generic Name: 20-gene prognostic assay Indication: Early stage breast cancer (luminal ER+/HER2-) Phase: Preclinical”
MSC is a 24-microRNA signature classifier for ischemic stroke
“Pipeline Candidate: MSC Generic Name: MicroRNA Signature Classifier Indication: Ischemic Stroke Phase: Phase 2”
Both assays are processed by partner EmeritusDx
“Partner: EmeritusDx Collaboration Terms: Laboratory responsible for processing, testing and reporting results.”
Risks & what to watch (4)›
Key risks
- Negative equity — Shareholders' equity of -$4.1M as of 2026-06-30 indicates liabilities exceed assets [sec].
- Minimal revenue — Revenue of only $0.1M with a net loss of -$0.3M for the period ended 2026-06-30 [sec].
- Preclinical stage lead asset — StemPrintER remains in preclinical phase with no near-term revenue expected [pipeline].
- LDT regulatory uncertainty — Both candidates are LDTs, subject to evolving FDA oversight and reimbursement risk [pipeline].
What to watch
- Any update on the preclinical development of StemPrintER and whether it advances to clinical validation [pipeline].
- Progress of the MSC Phase 2 study for ischemic stroke, including any interim data or completion timeline [pipeline].
- Changes in shareholders' equity and revenue in subsequent quarterly filings [sec].
- Regulatory developments regarding LDT oversight by the FDA that could affect both pipeline candidates [pipeline].
Sources: Competitor trials · Pipeline · Generated October 4, 2026 · How we verify sources →
Run Accustem Sciences Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Accustem Sciences Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
Cash runway data unavailable
Net income -$253K
Lead: Phase 2
2 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Financials
Governance
Frequently asked questions
What is the AI investment thesis for Accustem Sciences Inc.?
Accustem Sciences Inc. (ACUT) is a development-stage diagnostics company advancing two laboratory-developed tests (LDTs) — a 20-gene prognostic assay for early-stage breast cancer and a microRNA signature classifier for ischemic stroke — both processed through its partner EmeritusDx, with minimal revenue and negative shareholders' equity as of mid-2026.
What is Accustem Sciences Inc.'s lead drug candidate?
Accustem Sciences Inc.'s most advanced tracked candidate is MSC (Phase 2) for Ischemic Stroke.
Who is the CEO of Accustem Sciences Inc.?
Ms. Wendy E. Blosser is the chief executive officer of Accustem Sciences Inc. (ACUT).
Where is Accustem Sciences Inc. headquartered?
Accustem Sciences Inc. (ACUT) is headquartered in New York, NY, United States.
What therapeutic areas does Accustem Sciences Inc. focus on?
Accustem Sciences Inc. develops therapies across Oncology, Neurology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.